Administration of erythropoietin and its derivatives in renal disease: Advantages, mechanisms and concerns

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 1, 2007, Pages 79-84

  Gobe, Glenda C ^a,c   Endre, Zoltan H ^b   Johnson, David W ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASIALOERYTHROPOIETIN; CARBAMYLATED ERYTHROPOIETIN; CISPLATIN; CYCLOSPORIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT CYTOKINE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANEMIA; APOPTOSIS; CELL PROTECTION; CELL SURVIVAL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; HYPOXIA; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TUBULE NECROSIS; LOW DRUG DOSE; PLASMA HALF LIFE; RECEPTOR AFFINITY; REPERFUSION INJURY; REVIEW;

EID: 37249049317     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2007.07.001     Document Type: Review

References (43)

1. Li F., et al. Erythropoietin on a tightrope: Balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 13 (2004) 265-289
2. Maxwell P.H., et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int. 44 (1993) 1149-1162
3. Jelkmann W. Biochemistry and assays of EPO. In: Jelkmann W. (Ed). Erythropoietin: Molecular Biology and Clinical Use (2003), FP Graham Publishing, Johnson City, TN 35-63
4. Fliser D., et al. Mechanisms of disease: erythropoietin - and old hormone with a new mission?. Nat. Clin. Pract. Cardiovasc. Med. 3 (2006) 563-572
5. Kuriyama S., et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77 (1997) 176-185
6. Anagnostou A., et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 5978-5982
7. Juul S.E., et al. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev. 52 (1998) 235-249
8. Westenfelder C., et al. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 55 (1999) 808-820
9. Eid T., et al. Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis. J. Neuropathol. Exp. Neurol. 63 (2004) 73-83
10. Ghezzi P., and Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Diff. 11 Suppl. 1 (2004) S37-S44
11. Smith K.J., et al. The cardiovascular effects of erythropoietin. Cardiovasc. Res. 59 (2003) 538-548
12. Westenfelder C., and Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 58 (2000) 647-657
13. Bagnis C., et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol. Dial. Transplant. 16 (2001) 932-938
14. Yang C.W., et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB. J. 17 (2003) 1754-1755
15. Vesey D.A., et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol. Dial. Transplant. 19 (2004) 348-355
16. Vaziri N.D., et al. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am. J. Physiol. 266 3 Pt 2 (1994) F360-F366
17. Sharples E.J., et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J. Am. Soc. Nephrol. 15 (2004) 2115-2124
18. Patel N.S., et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 66 (2004) 983-989
19. Spandou E., et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol. Dial. Transplant. 21 (2006) 330-336
20. Johnson D.W., et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 69 (2006) 1806-1813
21. Erbayraktar S., et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6741-6746
22. Leist M., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242
23. De Los Santos J.F., and Thomas G.M. Anemia correction in malignancy management: Threat or opportunity?. Gynecol. Oncol. 105 (2007) 517-529
24. Bonventre J., and Weinberg J.M. Recent advances in the pathophysiology of ischemic acute renal failure. J. Am. Soc. Nephrol. 14 (2003) 2199-2210
25. Eddy A.A. Progression in chronic kidney disease. Adv. Chronic Kidney Dis. 12 (2005) 353-365
26. Goumenos D.S., et al. Apoptosis and myofibroblast expression in human glomerular disease: a possible link with ttransforming growth factor-beta-1. Nephron. 92 (2002) 287-296
27. Lane A., et al. Interacting roles of myofibroblasts, apoptosis and fibrogenic growth factors in the pathogenesis of renal tubulo-interstitial fibrosis. Growth Fact. 20 (2002) 109-119
28. Anver E.D., and Sweeney Jr. W.E. Renal cystic disease: new insights for the clinician. Pediatr. Clin. North Am. 53 (2006) 889-909 ix
29. Gobe G.C., and Axelsen R.A. Genesis of renal tubular atrophy in experimental hydronephrosis in the rat. Role of apoptosis. Lab. Invest. 56 (1987) 273-281
30. Shimizu A., et al. Apoptosis in progressive crescentic glomerulonephritis. Lab. Invest. 74 (1996) 941-951
31. Wan L., et al. The pathogenesis of septic acute renal failure. Curr. Opin. Crit. Care 9 (2003) 496-502
32. Bunn H.F. New agents that stimulate erythropoiesis. Blood 109 (2007) 868-873
33. Kang D.H., et al. Renoprotective effect of erythropoietin (EPO): possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney. Kidney Int. 67 (2005) 1683
34. Jungers P., et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol. Dial. Transplant. 16 (2001) 307-312
35. Gouva C., et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 66 (2004) 753-760
36. Bahlmann F.H., et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 64 (2003) 1648-1652
37. Bahlmann F.H., et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110 (2004) 1006-1012
38. Plotkin M.D., and Goligorsky M.S. Mesenchymal cells from adult kidney support angiogenesis and differentiate into multiple interstitial cell types including erythropoietin-producing fibroblasts. Am. J. Physiol. Renal. Physiol. 291 (2006) F902-F912
39. Lee S.H., et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am. J. Nephrol. 25 (2005) 64-76
40. Forman C., Vesey D.A., and Johnson D.W. Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology (Carlton) 11 (2006) 306-312
41. Imamura R., et al. Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. Biochem. Biophys Res. Commun. 353 (2007) 786-792
42. Li, J. et al. Effect of recombinant human erythropoietin (rhEpo) on renal cell carcinoma chemotherapy. Abstract, World Congress of Nephrology, Rio de Janeiro. Cancer Biol. Therapy, 2007, 221
43. Lai S.Y., et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24 (2005) 4442-4449